Northwire Canada EditionTuesday, July 14, 2026
Northwire
TLO 5.90 +11.1% ADE 0.135 +0.0% FAIR 0.055 +22.2% SVRS 0.425 −1.2% RES 0.035 +0.0% CYG 0.120 +0.0% MGG 0.315 −4.5% BUFF 0.770 +2.7% TKO 11.15 +11.9% MINK 0.100 −4.8% LCE 0.240 −4.0% AEF 0.160 +0.0% BEM 0.095 +5.6% APMI 0.120 +0.0% LIO 0.135 +3.9% TLO 5.90 +11.1% ADE 0.135 +0.0% FAIR 0.055 +22.2% SVRS 0.425 −1.2% RES 0.035 +0.0% CYG 0.120 +0.0% MGG 0.315 −4.5% BUFF 0.770 +2.7% TKO 11.15 +11.9% MINK 0.100 −4.8% LCE 0.240 −4.0% AEF 0.160 +0.0% BEM 0.095 +5.6% APMI 0.120 +0.0% LIO 0.135 +3.9%
Financings

JJK Holdings Ltd. Acquires $7,878,792 Convertible Debenture Of Noveris Health Sciences Inc.; Filing Of Early Warning Reports By JJK Holdings Ltd. And Pioneer Garage Limited

NVRS · Price

Executive Summary

  • JJK Holdings Ltd. acquired a CAD $7,878,792 convertible debenture previously held by Pioneer Garage Limited.
  • The debenture matures on October 14 2026 and is convertible at the greater of the 20‑day VWAP or the CSE‑minimum price; illustrative conversion could issue ~42.59 million shares (≈97.2% of outstanding shares).
  • No immediate transfer of the debenture to third parties is agreed, but JJK may do so in the future and may acquire additional securities of Noveris.

Key Details

  • Acquisition amount: CAD $7,878,792 principal.
  • Previous holder: Pioneer Garage Limited (formerly owned by Ray Van Empel).
  • Maturity date: October 14 2026.
  • Conversion price: Greater of (i) 20‑day trailing VWAP of Noveris common shares on conversion date, or (ii) CSE‑minimum permitted price.
  • Illustrative conversion assumptions: Using a $0.185 per share price (most recent CSE closing), the debenture could convert into 42,588,065 common shares, representing ~97.18% of the company’s 1,235,061 issued and outstanding shares.
  • Current ownership post‑acquisition: JJK holds the debenture; prior to acquisition Pioneer held it (which would have equated to ~97.18% ownership). Ray Van Empel now holds only 2 common shares (~0%).
  • Potential future actions: JJK may transfer all or part of the debenture to third parties and may acquire additional Noveris securities for investment purposes; no agreement currently exists for such transfers.
  • Early Warning reporting: The release satisfies NI 62‑103 and NI 62‑104 filing requirements; early warning reports are available on SEDAR+.

Notable Quotes

  • “The acquisition of the debenture by JJK represents a significant development in Noveris’ capital structure, and we will continue to keep shareholders informed as the situation evolves.” – Joshua Bartch, Chief Executive Officer.
Read the original news release →

More from Noveris Health Sciences Inc.